Page last updated: 2024-12-07
rhc 3164
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
7-chloro-5-propyl-1,2,4-triazolo(4,3-a)quinoxaline-1,4(2H,5H)-dione: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 133527 |
CHEMBL ID | 121101 |
MeSH ID | M0120009 |
Synonyms (9)
Synonym |
---|
rev 3164 |
(1,2,4)triazolo(4,3-a)quinoxaline-1,4(2h,5h)-dione, 7-chloro-5-propyl- |
7-chloro-5-propyl-1,2,4-triazolo(4,3-a)quinoxaline-1,4(2h,5h)-dione |
rhc-3164 |
rev-3164 |
rhc 3164 |
CHEMBL121101 |
80708-33-4 |
DTXSID90230516 |
Research Excerpts
Effects
Excerpt | Reference | Relevance |
---|---|---|
"RHC 3164 has been investigated for its antiallergic activities in 3 in vitro models of anaphylaxis. " | ( Antiallergic activity profiles in vitro of RHC 3164 and related compounds. II. Comparison of RHC 3164 with disodium cromoglycate. Dally-Meade, V; Huang, F; Jariwala, N; Khandwala, A, 1984) | 1.97 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (6)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID185586 | Percent inhibitory activity in rat passive cutaneous anaphylaxis test at a dose of 25 mg/kg administered perorally | 1985 | Journal of medicinal chemistry, Mar, Volume: 28, Issue:3 | 1,2,4-Triazolo[4,3-a]quinoxaline-1,4-diones as antiallergic agents. |
AID1859262 | Inhibition of IgE-mediated passive cutaneous anaphylaxis in rat when administered orally | 2022 | European journal of medicinal chemistry, Feb-05, Volume: 229 | Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities. |
AID1859261 | Inhibition of IgE-mediated passive cutaneous anaphylaxis in rat at 25 mg/kg, po | 2022 | European journal of medicinal chemistry, Feb-05, Volume: 229 | Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities. |
AID181354 | Concentration required to inhibit Antigen-induced release of Histamine from rat mast cells | 1985 | Journal of medicinal chemistry, Mar, Volume: 28, Issue:3 | 1,2,4-Triazolo[4,3-a]quinoxaline-1,4-diones as antiallergic agents. |
AID1859258 | Inhibition of antigen-induced release of histamine (AIR) from rat peritoneal mast cells (RMC) | 2022 | European journal of medicinal chemistry, Feb-05, Volume: 229 | Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities. |
AID177829 | Effective dose against IgE-mediated cutaneous anaphylaxis in the rat after peroral administration | 1985 | Journal of medicinal chemistry, Mar, Volume: 28, Issue:3 | 1,2,4-Triazolo[4,3-a]quinoxaline-1,4-diones as antiallergic agents. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 5 (83.33) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.50
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (16.67%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (83.33%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |